IPB-106
Pancreatic Ductal Adenocarcinoma (PDAC)
DiscoveryActive
Key Facts
About Interplay Bio
Interplay Bio is an early-stage biotech leveraging its LigandPro platform to pioneer Targeted Protein Degradation (TPD) drug discovery. The company's core technology identifies small molecule ligands that bind to diverse protein surfaces, including non-traditional pockets, to enable the degradation of challenging targets. With a pipeline of early-stage candidates and a focus on collaboration, Interplay Bio is positioning itself to address high-need therapeutic areas like oncology and neurodegenerative diseases. The company is currently pre-revenue and seeking partnerships to advance its programs.
View full company profileTherapeutic Areas
Other Pancreatic Ductal Adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| M2T™ Program (unspecified) | Leukogene Therapeutics | Preclinical |
| IPB-107 | Interplay Bio | Discovery |
| PurIST® | GeneCentric Therapeutics | Commercial |
| SIWA318H | SIWA Therapeutics | Preclinical |